€ million |
|
Note |
|
2022 |
|
2021 |
|---|---|---|---|---|---|---|
Profit after tax |
|
|
|
3,339 |
|
3,065 |
Items of other comprehensive income that will not be reclassified to profit or loss in subsequent periods |
|
|
|
|
|
|
Net defined benefit liability |
|
|
|
|
|
|
Changes in remeasurement |
|
|
|
1,440 |
|
751 |
Tax effect |
|
|
|
-300 |
|
-119 |
Changes recognized in equity |
|
|
|
1,140 |
|
632 |
Equity instruments |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
-34 |
|
-41 |
Tax effect |
|
|
|
3 |
|
8 |
Changes recognized in equity |
|
|
|
-31 |
|
-33 |
|
|
|
|
1,109 |
|
599 |
Items of other comprehensive income that may be reclassified to profit or loss in subsequent periods |
|
|
|
|
|
|
Cash flow hedge reserve |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
-98 |
|
-127 |
Reclassification to profit or loss |
|
|
|
194 |
|
27 |
Reclassification to assets |
|
|
|
– |
|
– |
Tax effect |
|
|
|
-5 |
|
5 |
Changes recognized in equity |
|
|
|
91 |
|
-95 |
Cost of cash flow hedge reserve |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
-15 |
|
-13 |
Reclassification to profit or loss |
|
|
|
16 |
|
27 |
Reclassification to assets |
|
|
|
– |
|
– |
Tax effect |
|
|
|
10 |
|
-3 |
Changes recognized in equity |
|
|
|
11 |
|
11 |
Currency translation difference |
|
|
|
|
|
|
Changes taken directly to equity |
|
|
|
1,228 |
|
1,730 |
Reclassification to profit or loss |
|
|
|
-71 |
|
-6 |
Changes recognized in equity |
|
|
|
1,157 |
|
1,724 |
|
|
|
|
1,259 |
|
1,640 |
Other comprehensive income |
|
|
|
2,368 |
|
2,239 |
Comprehensive income |
|
|
|
5,708 |
|
5,304 |
thereof: attributable to shareholders of Merck KGaA, Darmstadt, Germany |
|
|
|
5,696 |
|
5,289 |
thereof: attributable to non-controlling interests |
|
|
12 |
|
15 |